XML 13 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Option and License Agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 60 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2024
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development $ 18,960 $ 10,370    
Net loss (16,746) $ (5,200)    
Accounts receivable 3,685     $ 3,467
Forecast | AbbVie        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront fees received     $ 100,000  
Collaboration and option agreement with AbbVie        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Deferred revenue 82,500      
Research and development 4,500      
Revenue related to research services 3,400      
Research collaboration and option agreement | Janssen        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Research and development 1,700      
Revenue related to research services 2,200      
Accounts receivable 3,700     $ 3,500
Deferred revenue $ 8,000